Equites Radar

INSP · Inspire Medical Systems, Inc.

Medical DevicesUnited StatesAnalyst view: Hold

$72.47

+6.39% last session

End-of-day data · close of 2026-09-11

Mildly bullish3 bullish · 2 bearish technical signals
Consensus: Hold (2.71 from 15 analysts)
To mean target: -11.3%

Market cap

$2B

Enterprise value

$2B

Trailing P/E

15.0

Forward P/E

44.3

Dividend yield

Beta

0.70

Avg volume

1M

Employees

1K

Daily Change %

6.39%

5 Days Change

5.39%

10 Days Change

5.54%

30 Days Change

12.43%

60 Days Change

28.44%

Month to Day Change

8.06%

Year to Day Change

-27.92%

Analyst Outlook

Consensus ratingHold
Recommendation mean (1–5)2.71
Covering analysts15
Mean price target$60.40
Low price target$40.00
Upside to mean target-11.3%

Analyst estimates change daily — follow the shifts on the Estimate Trends page.

Technical Analysis

RSI (14)75.7
50-day MA$56.78
200-day MA$65.83
Price vs 50-day MA+27.6%
Price vs 200-day MA+10.1%
MACD histogram0.61
Volume vs 3-month avg0.8×
52w low $40.0552w high $143.99

Analyst sentiment over time — INSP

Rec Mean (blue, left — higher = more bullish) vs. price targets (right).

Investment Bank Ratings as of 2026-09-11

Latest call per bank · past 12 months

JP Morgan

Neutral

$60.00

-11.9% vs price
▲ raised from $54.00Maintains · 2026-08-04

RBC Capital

Sector Perform

$45.00

-33.9% vs price
▼ cut from $56.00Maintains · 2026-05-05

Wells Fargo

Equal-Weight

$56.00

-17.8% vs price
▼ cut from $70.00Maintains · 2026-05-05

Jefferies

Hold

$66.00

-3.1% vs price
▼ cut from $81.00Maintains · 2026-02-12

UBS

Neutral

$91.00

+33.6% vs price
▲ raised from $89.00Maintains · 2025-12-23

Morgan Stanley

Equal-Weight

$130

+90.8% vs price
▲ raised from $105Downgrade · 2025-12-02

Recent rating actions

DateFirmActionRatingPrice target
2026-09-11StifelMaintainsBuy$75.00 $80.00
2026-08-04JP MorganMaintainsNeutral$54.00 $60.00
2026-08-04MizuhoMaintainsOutperform$55.00 $65.00
2026-08-04OppenheimerUpgradePerformOutperform$0.00 $85.00
2026-08-04Truist SecuritiesReiteratesHold$54.00 $62.00
2026-08-04Evercore ISI GroupMaintainsIn-Line$40.00 $54.00
2026-08-04Piper SandlerMaintainsNeutral$55.00 $60.00
2026-08-04BairdMaintainsNeutral$54.00 $59.00

Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.

Signal Summary as of 2026-09-11

  • RSI (14): RSI is 76 — overbought territory; the recent run-up may be due for a pause.
  • Price vs 50-day MA: Trading 27.6% above the 50-day MA ($56.78).
  • Price vs 200-day MA: Trading 10.1% above the 200-day MA ($65.83).
  • MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
  • MACD (12,26,9): MACD histogram is positive (+0.60) — short-term momentum is improving.
  • 52-week range: Price sits between the 52-week low ($40.05) and high ($143.99).

INSP Price Chart

Loading chart for INSP

Fundamentals

Revenue (TTM)$1.0B
EBITDA$0M
Free cash flow$0M
Operating cash flow$0M
Book value / share$28.56
Net Debt / EBITDA-4.1
WACC9.0%
Revenue growth-8.00%
Earnings growth

About Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for patients with moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.

More in Medical Devices

Screen INSP against the full market on the Radar →

Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.